PH eyeing additional 60 M COVID-19 vaccines for younger population | Inquirer News

PH eyeing additional 60 M COVID-19 vaccines for younger population

/ 01:27 PM June 07, 2021

Vials labelled "AstraZeneca, Pfizer - Biontech, Johnson&Johnson, Sputnik V coronavirus disease (COVID-19) vaccine" are seen in this illustration picture

Reuters

MANILA, Philippines — The Philippines is eyeing to increase its supply of COVID-19 vaccines by around 60 million doses to address to be  inoculation requirements of the country’s younger population, vaccine czar Sec. Carlito Galvez Jr. said.

In a public briefing, Galvez said the government is negotiating with vaccine manufacturers to increase the country’s vaccine supply from 158 million to over 200 million doses.

Article continues after this advertisement

“Yung pediatric vaccination, may 39 million po tayo na population diyan. Ang implication niyan, we need to buy more vaccines. More or less 60 million (doses),” Galvez said.

FEATURED STORIES

(For pediatric vaccination, we have to cater to around 39 million.  The implication of that is we need to buy more vaccines. More or less 60 million doses.)

“So ang ginawa po natin, ongoing po ng ating mga negotiations sa ating mga pharmaceutical at vaccine companies para at least mag-increase tayo from the original 158 million to 202 million, kasama na po yung COVAX [facility],” he added.

Article continues after this advertisement

(So what we are doing is we are negotiating with  pharmaceutical and vaccine companies so that we can increase our original target of 158 million to 202 million doses, including those under the COVAX facility.)

Article continues after this advertisement

Earlier, the United States Food and Drug Administration approved the use of the Pfizer-BioNTech COVID-19 vaccine for children aged 12 to 15.

Article continues after this advertisement

Moderna, for its part, will be submitting its findings of its adolescent study to the U.S. Food and Drug Administration and other regulators for emergency use authorization in early June.

Moderna’s study showed that the COVID-19 vaccine it developed was effective in adolescents aged 12-17 and showed no new or major safety problems in a clinical trial.

Article continues after this advertisement

Meanwhile, Sinovac’s COVID-19 jab was able to secure Chinese authorization for the use of its vaccine on people aged between three and 17.

gsg
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: COVID-19 Vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.